Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- Sep 21 2020 Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
- Sep 15 2020 Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
- Sep 3 2020 Oramed to Present at H.C. Wainwright Global Investment Conference
- Jul 15 2020 Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
- Jun 15 2020 Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin